New Insight: Phase 2 BEHOLD Study and UBX1325 for DME, Live at AAO 2023
On the floor at AAO 2023, host Veeral Sheth, MD, and producer Connor Iapoce discuss UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.
Episode Highlights:
0:30 Introduction
0:48 Background into UBX1325 and BEHOLD
2:49 BEHOLD 48-week results
6:05 Next steps
6:56 Conclusion
Please direct any podcast-related inquiries to ciapoce@mjhlifesciences.com.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.